rPFS in patients with any HRR gene alteration (assessed by blinded independent central review; HRR-deficient intention-to-treat population).
EVENT
rPFS was compared between treatment groups using stratified log-rank test. HRs and associated 95% two-sided CIs were estimated by a Cox proportional hazards model. Median time to event was estimated by the Kaplan–Meier method, and 95% CIs were based on the Brookmeyer–Crowley method. The A consistent treatment effect for rPFS was observed across prespecified clinical subgroups (Fig. 